An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Status: Recruiting

Eligibility Criteria

Sex: All
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- locally advanced or metastatic disease of breast, lung, head and neck, gastric, gastroesophageal junction, or esophagus, that is not amenable to curative intent treatment - evidence of progression on or after the last regimen received - restricted strenuous activity but able to walk carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for specific requirements by type of cancer

Exclusion Criteria:

- study staff will review

Conditions & Interventions

Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Locally Advanced or Metastatic Malignant Solid Tumors, Metastatic Cancer

More Information

Description: One goal of this study is to find out if enfortumab vedotin is effective and safe as a treatment for people with breast, lung, head and neck, gastric, gastroesophageal junction, or esophageal cancer. Researchers will look at how enfortumab vedotin can act in the body. Enfortumab vedotin is expected to work by attacking cells that have a protein called Nectin-4, commonly found in cancer cells. Another goal of this study is to find out if enfortumab vedotin is effective and safe when combined with another US Food and Drug Administration (FDA) approved medicine, pembrolizumab (brand name KEYTRUDA®), and used as a treatment for people with head and neck cancer who have not received previous chemotherapy treatment other than the chemotherapy that may have been given in combination with radiation therapy or right before or right after surgery in the past.
Study Contact: Naomi Fujioka - fujio002@umn.edu
Principal Investigator: Naomi Fujioka
Phase: Phase 2
IRB Number: SITE00001051